We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inflammatory Cytokine Levels Predict Patient Outcomes After Traumatic Injury

By LabMedica International staff writers
Posted on 09 Nov 2021
Measurement of the inflammatory cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8) can be used to predict patient outcomes after traumatic injury.

Cytokines are peptides, which are important in cell signaling but cannot cross the lipid bilayer of cells to enter the cytoplasm. More...
Cytokines have been shown to be involved in autocrine, paracrine, and endocrine signaling as immuno-modulating agents. They act through cell surface receptors and are especially important in the immune system where they modulate the balance between humoral and cell-based immune responses and regulate the maturation, growth, and responsiveness of particular cell populations.

Traumatic injury is the leading cause of mortality in patients under the age of 50. It is associated with a complex inflammatory response involving hormonal, immunologic, and metabolic mediators. The marked elevation of cytokines and inflammatory mediators subsequently correlates with the development of post-traumatic complications.

Investigators at the University of Kentucky (Lexington, USA) sought to determine whether elevated cytokine levels provided a predictive value for orthopedic trauma patients. For this study they measured IL-6, IL-8, IL-10, and migration inhibitory factor levels in samples obtained from 58 patients with an average age of 40 years who had experienced severe bone, joint, and muscle trauma. Six of the patients (10%) suffered pulmonary complications and five (9%) had acute kidney injury.

Results revealed that addition of IL-6 levels to baseline models significantly improved prediction of pulmonary complication and hospital length of stay. The addition of IL-8 significantly improved the prediction of acute kidney injury. The addition of post-injury IL-6 level to the baseline New Injury Severity Score (NISS) model was better able to predict the occurrence of pulmonary complications as well as prolonged ICU and hospital length of stay.

“This is the first time we have combined parameters of external anatomic injury (NISS) with parameters of the internal physiologic response to injury (cytokines) to determine trauma patient outcomes,” said first author Dr. Arun Aneja, assistant professor of orthopedics at the University of Kentucky.

The study was published in the November 2, 2021, online edition of the Journal of Orthopaedic Research.

Related Links:
University of Kentucky


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.